{"id":2414,"date":"2025-01-14T10:59:40","date_gmt":"2025-01-14T07:59:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2414"},"modified":"2025-03-07T14:58:30","modified_gmt":"2025-03-07T11:58:30","slug":"edgewise-therapeutics-announces-plans-for-2025","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/edgewise-therapeutics-announces-plans-for-2025\/","title":{"rendered":"Edgewise Therapeutics gibt Pl\u00e4ne f\u00fcr 2025 bekannt"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Edgewise Therapeutics has announced its 2025 plans for Duchenne muscular dystrophy. The company said in a statement that it will prioritize Sevasemten.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. There are currently no approved therapies for individuals with Becker, a serious genetic, progressive neuromuscular disorder. [Read More: <a href=\"https:\/\/dmdwarrior.com\/differences-between-dmd-and-bmd\/\" target=\"_blank\" rel=\"noreferrer noopener\">Differences Between DMD and BMD?<\/a>]<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Complete recruitment of the GRAND CANYON pivotal placebo-controlled cohort in the first quarter of 2025<\/li>\n\n\n\n<li>Seek end of Phase 2 feedback from the U.S. Food and Drug Administration (FDA) on CANYON results for sevasemten in Becker in the first half of 2025<\/li>\n\n\n\n<li>Report data from the Phase 2 LYNX and FOX trials in the first half of 2025 and outline potential Phase 3 plans in individuals with Duchenne<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Edgewise Therapeutics has announced its 2025 plans for Duchenne muscular dystrophy. The company said in a statement that it will prioritize Sevasemten. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies including Becker and Duchenne. There are currently no approved therapies for individuals with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2417,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[67,66,151,152,150],"class_list":["post-2414","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-becker-muscular-dystrophy","tag-duchenne-muscular-dystrophy","tag-edgewise","tag-edgewise-therapeutics","tag-sevasemten"],"subtitle":"Edgewise Therapeutics, eines der f\u00fchrenden biopharmazeutischen Unternehmen f\u00fcr Muskelerkrankungen, gab heute Unternehmensupdates bekannt und skizzierte seine Ziele f\u00fcr 2025. Auf der heutigen j\u00e4hrlichen JP Morgan Healthcare Conference wird Dr. Kevin Koch, CEO von Edgewise, diese Updates geben.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/2414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=2414"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/2414\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/2417"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=2414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=2414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=2414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}